Over the past decade, there have been promising data supporting specific delivery of GzmB using genetic fusion with an antibody or derivative of natural ligands to extracellular surface receptors as a therapeutic tool to combat cancer by increasing expression of pro-apoptotic genes and decreasing the tumor burden in mice. Here, GZMB is linked to cancer.